# Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

> **NCT05319249** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **German Cancer Research Center** · enrollment: 54 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** NK cells
- **DRUG:** Talazoparib 1 MG [Talzenna]

## Key facts

- **NCT ID:** NCT05319249
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319249, "Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05319249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*